Status:

RECRUITING

Cognitive and Vascular Functioning Following TBI

Lead Sponsor:

Walter Reed National Military Medical Center

Collaborating Sponsors:

Johns Hopkins University

Conditions:

Traumatic Brain Injury

Cognitive Decline

Eligibility:

All Genders

18-74 years

Brief Summary

This observational study will examine the association of chronic traumatic cerebrovascular injury and cardiovascular risk factors with TBI-related cognitive impairment and vascular dementia. Cerebrova...

Detailed Description

The investigators will enroll 300 Service Members (SMs) and Veterans who participated in the National Intrepid Center of Excellence (NICoE) intensive outpatient program or Defense and Veterans Brain I...

Eligibility Criteria

Inclusion

  • Active duty uniformed SM or Veteran who is currently eligible for treatment at WRNMMC (i.e., Defense Enrollment Eligibility Reporting System (DEERS)-eligible).
  • Ability to read, write, and speak English.
  • Ability to provide informed consent.
  • NICoE Intensive Outpatient Program (IOP) or NatHx Study comprehensive evaluation ≥3 years prior to current evaluation with valid neuropsychological test results.
  • Consent to allow access to prior research data collected through the NICoE TBI Neuroimaging Core Project or NatHx Study and consent to allow access to at least 1 prior blood specimen previously collected through these studies or the DoD Serum Biorepository.
  • Additional TBI Inclusion Criteria
  • 1\. History of at least one mild, moderate, severe, or penetrating TBI \> 3 years prior to enrollment. TBI will be diagnosed if any one of the following criteria immediately after the injury is met and attributed to the brain injury, rather than environmental/psychological/other injury factors (DoD-VA criteria246):
  • Loss of consciousness (LOC) or post-traumatic amnesia (PTA)
  • Alteration of consciousness (AOC)
  • Evidence of neurologic dysfunction
  • TBI-related abnormality on structural neuroimaging (either CT or MRI). Additional Healthy Control Criteria
  • History of military deployment.
  • Low history of blast exposure (i.e., \<10 blasts) Additional Blast Control Criteria
  • <!-- -->
  • History of significant blast exposure (i.e., exposure to ≥ 10 blasts)

Exclusion

  • Disabling neurologic or psychological disorders such as autism, cerebral palsy, developmental disorder, stroke, brain tumor, multiple sclerosis, meningitis, encephalitis, brain abscess, vascular malformation, pre-injury epilepsy, schizophrenia, bipolar disorder, personality disorder
  • Diabetes mellitus requiring drug treatment
  • Hypertension requiring more than 1 antihypertensive drug to control BP
  • History of myocardial infarction or other systemic vasculopathies
  • Dementia diagnosis at initial NICoE/NatHx Study assessment

Key Trial Info

Start Date :

November 27 2023

Trial Type :

OBSERVATIONAL

Allocation :

ESTIMATED

End Date :

May 1 2027

Estimated Enrollment :

300 Patients enrolled

Trial Details

Trial ID

NCT06034509

Start Date

November 27 2023

End Date

May 1 2027

Last Update

September 26 2025

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Walter Reed National Military Medical Center

Bethesda, Maryland, United States, 20889